The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
RISPERIDONE GENERICHEALTH (Generic Health Pty Ltd)
Product name
RISPERIDONE GENERICHEALTH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
45 working days (45)
Active ingredients
risperidone
Registration type
EOI
Indication
Generic medicine
RISPERIDONE GENERICHEALTH (tablets) are now also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the Alzheimer type. (see Section 4.2 Dose and Method of Administration: Behavioural Disturbances in Dementia)